Pulmonary Vascular Dysfunction as a Cause of Persistent Exertional Dyspnea After Coronavirus Disease (COVID-19)

Last updated: May 7, 2024
Sponsor: University of Giessen
Overall Status: Active - Recruiting

Phase

N/A

Condition

Covid-19

Treatment

pulmonary vascular dysfunction

pulmonary vascular function

Clinical Study ID

NCT05374577
KKS-300
  • Ages > 18
  • All Genders

Study Summary

To identify pulmonary vascular disease in post/long-COVID-19 patients as a cause of dyspnea/exercise limitation and to differentiate it from other causes of dyspnea

Eligibility Criteria

Inclusion

Inclusion Criteria:

  • Age ≥ 18 years, patients with a suspected diagnosis of post/long-COVID-19 syndrome whopresent to our pneumology or infectious disease outpatient clinic or correspondingward from the start of the study and whose SARS-CoV-2 infection was diagnosed at least 3 and not longer than 18 months prior to presentation
  • Patients at least 3 and not longer than 18 months after a SARS-CoV-2 infection withoutpost/long-COVID-19 syndrome who present to our post-infection outpatient clinic forfollow-up

Exclusion

Exclusion Criteria:

  • Patients who refuse to participate in the study
  • Severe underlying chronic pulmonary, cardiac, or systemic disease (e.g., Chronicobstructive pulmonary disease (COPD), severe heart failure, neuromuscular disease)that was diagnosed prior to acute COVID-19 disease and whose progression appearslikely as the cause of dyspnea
  • Other non pneumologic causes of dyspnea (e.g., hemoglobin < 100 g/L)
  • Unstable or acute disease (e.g., acute infection, acute renal failure, acute coronarysyndrome)
  • Inability to perform spiroergometry, including transient orthopedic problems,contraindications to central venous and arterial catheter placement (e.g., severebleeding tendency).

Study Design

Total Participants: 200
Treatment Group(s): 2
Primary Treatment: pulmonary vascular dysfunction
Phase:
Study Start date:
April 15, 2022
Estimated Completion Date:
June 30, 2025

Study Description

The aim is to identify pulmonary vascular disease in post/long-COVID-19 patients as a cause of dyspnea/exercise limitation and to differentiate it from other causes of dyspnea (muscular, left cardiac, psychological, deconditioning-related causes) by investigating ventilation-perfusion (V/Q) mismatch and (exercise-induced) pulmonary hypertension (PH) or right heart dysfunction.

Connect with a study center

  • Natascha Sommer

    Giessen,
    Germany

    Active - Recruiting

Not the study for you?

Let us help you find the best match. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.